April 1st 2025
Novavax’s COVID-19 vaccine, Merck’s RSV antibody, and Innoviva’s gonorrhea antibiotic await regulatory decisions this quarter.
Controversy Arises on Added Benefit of Rilpivirine for HIV-Positive Children and Adolescents
May 2nd 2016In a one-arm study examined by the German Institute for Quality and Efficiency in Health Care (IQWiG), the added benefit of rilpivirine for HIV-positive children and adolescents between the ages of 12 and 18, was not proven, contrary to the belief of the manufacturer.
Read More
Study Shows HIV Can Develop Resistance to Promising HIV Therapy
April 28th 2016A recent study has shown that although the CRISPR/Cas9 gene editing technology can stop human immunodeficiency virus (HIV) replication, it also results in unexpected viral resistance and thereby limits use of the technology in HIV therapy.
Read More
Study Challenges WHO Recommendation to Increase HCV Screening in HIV-Infected Populations
April 27th 2016In a recent study of 1,812 human immunodeficiency virus (HIV)-infected individuals in sub-Saharan Africa, researchers found that none of these individuals had confirmed hepatitis C virus replication.
Read More
Age-related Diseases Don't Occur Earlier in HIV-infected Patients
November 6th 2014Despite previous research suggesting HIV patients have an increased likelihood of suffering from a heart attack, kidney failure, or cancer, Johns Hopkins Bloomberg School of Public Health investigators showed the age they encounter these conditions were similar to their uninfected counterparts.
Read More
How Obamacare Will Affect HIV/AIDS Prevention
June 19th 2014Noting successful HIV/AIDS prevention efforts rely on early diagnosis, an analysis estimates that improved access to health insurance through the Affordable Care Act will increase the number of patients getting tested for HIV by nearly 500,000 over a 5-year period, though that impact would be amplified if all US states opted to expand Medicaid coverage.
Read More